Advanced Non-Small Cell Lung CancerFor Patients Previously Treated with
OPDIVO® (nivolumab) is a prescription medicine used to treat a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.
For Patients with Metastatic Melanoma
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
Advanced Renal Cell CarcinomaFor Previously Treated Patients with
OPDIVO® (nivolumab) is a prescription medicine used to treat kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other medications.
Followed by Adcetris® (brentuximab vedotin)For Adults with cHL Whose Cancer has Come Back or Spread After an Autologous Stem Cell Transplant
OPDIVO® (nivolumab) is a prescription medicine used to treat classical Hodgkin lymphoma (a type of blood cancer that affects white blood cells known as lymphocytes) if your cancer has come back or spread after you had an autologous stem cell transplant (a type of stem cell transplant that uses your own stem cells) and were treated with the drug Adcetris® (brentuximab vedotin) after stem cell transplant.
It is not known if OPDIVO is safe and effective in children less than 18 years of age.
OPDIVO is a medicine that may treat your melanoma, lung cancer, kidney cancer, or blood cancer by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. Some of these problems may happen more often when OPDIVO is used in combination with YERVOY.
YERVOY can cause serious side effects in many parts of your body which can lead to death. These problems may happen anytime during treatment with YERVOY or after you have completed treatment.
Additional serious side effects observed during a separate study of YERVOY alone include:
Your healthcare provider will check you for these problems during treatment. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment, if you have severe side effects.
Tell your healthcare provider if you are pregnant or plan to become pregnant. OPDIVO and YERVOY can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during and for at least 5 months after the last dose of OPDIVO. Talk to your healthcare provider about birth control methods that you can use during this time. Tell your healthcare provider right away if you become pregnant during treatment. Before receiving treatment, tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of YERVOY.
The most common side effects of OPDIVO, when used in combination with YERVOY include: feeling tired; diarrhea; fever; shortness of breath; rash; nausea; and vomiting. The most common side effects of YERVOY include: tiredness; diarrhea; itching; rash; nausea; vomiting; headache; weight loss; fever; decreased appetite; and difficulty falling or staying asleep.
The most common side effects of OPDIVO in people with non-small cell lung cancer include: feeling tired; pain in muscles, bones, and joints; decreased appetite; cough; and constipation.
The most common side effects of OPDIVO in people with renal cell carcinoma include: feeling tired; shortness of breath; pain in the muscles, bones, and joints; decreased appetite; cough; nausea; diarrhea; constipation; and rash.
The most common side effects of OPDIVO in people with classical Hodgkin lymphoma include: feeling tired; upper respiratory tract infection; fever; diarrhea; and cough.
These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Information provided in this website is not a substitute for talking with your healthcare professional. Your healthcare professional is the best source of information about your disease.
All individuals depicted are models used for illustrative purposes only.
Would you like to leave this site?
This Internet site may provide links or references to other sites.
BMS has no responsibility for the content of such other sites and
is not liable for any damages or injury arising from that content.
Any links to other sites are provided merely as a convenience to the
users of this Internet site.